Literature DB >> 25612863

Severe hematologic complications after lung transplantation in patients with telomerase complex mutations.

Raphael Borie1, Caroline Kannengiesser2, Sandrine Hirschi3, Jérôme Le Pavec4, Hervé Mal5, Emmanuel Bergot6, Stéphane Jouneau7, Jean-Marc Naccache8, Patrick Revy9, David Boutboul10, Régis Peffault de la Tour11, Lidwine Wemeau-Stervinou12, Francois Philit13, Jean-François Cordier13, Gabriel Thabut4, Bruno Crestani14, Vincent Cottin13.   

Abstract

BACKGROUND: Mutations in the telomerase complex (TERT and TR) are associated with pulmonary fibrosis and frequent hematologic manifestations. The aim of this study was to characterize the prognosis of lung transplantation in patients with TERT or TR mutations.
METHODS: Patients with documented TERT or TR mutations who received a lung transplant between 2007 and 2013 in France were identified via an exhaustive search of the lung transplantation network, one expert genetic laboratory, and the clinical research network on rare pulmonary diseases.
RESULTS: There were 9 patients (7 men) with TERT (n = 6) or TR (n = 3) mutations who received a single (n = 8) or a double (n = 1) lung transplant for pulmonary fibrosis. Median age was 50 years (range, 35-61 years) at diagnosis and 52 years (range, 37-62 years) at the time of lung transplantation. Thrombocytopenia was present in 7 patients before lung transplantation. After lung transplantation, 6 patients developed myelodysplasia and/or bone marrow failure, directly contributing to death in 4 cases. Anemia was observed in 9 patients, and neutropenia was observed in 3 patients. The median survival after lung transplantation was 214 days (range, 59-1,709 days).
CONCLUSIONS: Patients with mutations of the telomerase complex are at high risk of severe hematologic complications after lung transplantation, in particular, bone marrow failure. Specific recommendations should be developed for appropriate guidance regarding hematologic risk assessment before transplantation and management of the post-transplantation immunosuppressive regimen.
Copyright © 2015 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  familial; genetics; idiopathic pulmonary fibrosis; myelodysplastic syndromes; thrombocytopenia

Mesh:

Substances:

Year:  2014        PMID: 25612863     DOI: 10.1016/j.healun.2014.11.010

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  31 in total

1.  Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post-lung transplantation survival.

Authors:  Chad A Newton; Julia Kozlitina; Jefferson R Lines; Vaidehi Kaza; Fernando Torres; Christine Kim Garcia
Journal:  J Heart Lung Transplant       Date:  2017-02-04       Impact factor: 10.247

Review 2.  Telomeres in Interstitial Lung Disease: The Short and the Long of It.

Authors:  Andrew M Courtwright; Souheil El-Chemaly
Journal:  Ann Am Thorac Soc       Date:  2019-02

3.  An Exome Sequencing Study to Assess the Role of Rare Genetic Variation in Pulmonary Fibrosis.

Authors:  Slavé Petrovski; Jamie L Todd; Michael T Durheim; Quanli Wang; Jason W Chien; Fran L Kelly; Courtney Frankel; Caroline M Mebane; Zhong Ren; Joshua Bridgers; Thomas J Urban; Colin D Malone; Ashley Finlen Copeland; Christie Brinkley; Andrew S Allen; Thomas O'Riordan; John G McHutchison; Scott M Palmer; David B Goldstein
Journal:  Am J Respir Crit Care Med       Date:  2017-07-01       Impact factor: 21.405

Review 4.  Pulmonary fibrosis in the era of stratified medicine.

Authors:  Susan K Mathai; Chad A Newton; David A Schwartz; Christine Kim Garcia
Journal:  Thorax       Date:  2016-10-31       Impact factor: 9.139

5.  Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations.

Authors:  Simone Feurstein; Ayodeji Adegunsoye; Danijela Mojsilovic; Rekha Vij; Allison H West DePersia; Padma Sheila Rajagopal; Afaf Osman; Robert H Collins; Raymond H Kim; Steven D Gore; Peter Greenberg; Lucy A Godley; Zejuan Li; Daniela Del Gaudio; Hari Prasanna Subramanian; Soma Das; Tom Walsh; Suleyman Gulsuner; Jeremy P Segal; Aliya N Husain; Sandeep Gurbuxani; Mary-Claire King; Mary E Strek; Jane E Churpek
Journal:  Blood Adv       Date:  2020-10-13

6.  Clinical outcomes of lung transplant recipients with telomerase mutations.

Authors:  Sofya Tokman; Jonathan P Singer; Megan S Devine; Glen P Westall; John-David Aubert; Michael Tamm; Gregory I Snell; Joyce S Lee; Hilary J Goldberg; Jasleen Kukreja; Jeffrey A Golden; Lorriana E Leard; Christine K Garcia; Steven R Hays
Journal:  J Heart Lung Transplant       Date:  2015-05-11       Impact factor: 10.247

7.  Telomeres revisited: RTEL1 variants in pulmonary fibrosis.

Authors:  Jonathan A Kropski; James E Loyd
Journal:  Eur Respir J       Date:  2015-08       Impact factor: 16.671

Review 8.  Lung transplantation at Duke.

Authors:  Alice L Gray; Michael S Mulvihill; Matthew G Hartwig
Journal:  J Thorac Dis       Date:  2016-03       Impact factor: 2.895

9.  Familial pulmonary fibrosis: a world without frontiers.

Authors:  Raphael Borie; Bruno Crestani
Journal:  J Bras Pneumol       Date:  2019-10-07       Impact factor: 2.624

Review 10.  Familial Pulmonary Fibrosis: Genetic Features and Clinical Implications.

Authors:  David Zhang; Chad A Newton
Journal:  Chest       Date:  2021-06-26       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.